Disorders of lipid metabolism. Clinical Guidelines 2023

Ezhov, M.; Кухарчук, В. В.; Сергиенко, И. В.; Alieva, A.; Antsiferov, M.B. Antsiferov; Аншелес, А. А.; Arabidze, G.; Аронов, Д. М.; Arutyunov, G. P.; Ахмеджанов, Н. М.; Балахонова, Т. В.; Барбараш, О. Л.; Boytsov, S. А.; Бубнова, М. Г.; Воевода, М. И.; Galstyan, Gagik Radikovich; Galyavich, А. S.; Gornyakova, N. B.; Gurevich, V.S.; Дедов, И И; Galstyan, Gagik R.; Duplyakov, D. V.; Eregin, Sergey; Ершова, А. И.; Irtyuga, O. B.; Карпов, Р. С.; Karpov, Yu. A.; Качковский, М. А.; Kobalava, Zh. D.; Козиолова, Н. А.; Konovalov, G A; Константинов, В. О.; Космачева, Е. Д.; Kotovskaya, Yu. V.; Мартынов, А. И.; Мешков, А. Н.; Небиеридзе, Д. В.; Nedogoda, S. V.; Обрезан, А. Г.; Олейников, В. Э.; Pokrovsky, S.; Ragino, Yu. I.; Rotar, O.; Skibitsky, V. V.; Smolenskaya, O. G.; Соколов, А. А.; Сумароков, А. Б.; Филиппов, Е. В.; Halimov, Yu. S.; Чазова, И Е; Шапошник, И. И.; Shestakova, Marina Vladimirovna; Yаkushin, S. S.; Shlyakhto, Е. V.

doi:10.15829/1560-4071-2023-5471

Cited by 73 publications

(7 citation statements)

References 223 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Statins are one of the most studied classes of drugs for primary and secondary prevention of CVD. If the target LDL level is not achieved on a maximal dose statin, it is recommended to add an inhibitor of cholesterol absorption, ezetimibe [38]. Ezetimibe monotherapy may be considered for patients with statin intolerance, but such approach has not been studied in randomized clinical trials.…”

Section: The Role Of Imaging Methods In Evaluating the Effectiveness ...mentioning

confidence: 99%

See 1 more Smart Citation

Detection and Stabilization of Vulnerable Plaques in the Coronary Arteries

Bikbaeva¹,

Kovalskaya²,

Rodin³

et al. 2023

Preprint

View full text Add to dashboard Cite

Background: Atherosclerotic plaque (AP) vulnerability can be assessed by coronary artery imaging techniques. Modern lipid-lowering therapy (LLT) has a stabilizing effect on the AP and reduces the likelihood of progression of vascular remodeling. Methods: Databases searched comprised PubMed, and the Web of Science up to April 2023. In total, 8 relevant articles were selected, and all of them are original clinical studies. Results Based on the results of ODISSEY-J-IVUS, there was a decrease in the percentage change in the normalized total volume of AP by 3.1% in the monotherapy group and by 4.8% in the combined LLT group (p = 0.23). According to GLACOV study normalized total atheroma volume decreased by 0.9 mm3 in the placebo group and by 5.8 mm3 in the evolocumab group (95% CI -7.3 -2.5; p<0.001). Plaque regression was observed in 64.3% of patients receiving evolocumab versus 47.3% of those on placebo. The dynamics of the minimum thickness of the fibrous cap varied within 18.0-62.67 microns while on combined LLT and 13.2-33.19 microns on monotherapy (PACMAN-AMI, Gao F). In the HUYGENS study, a lipid arc regression of 57.5° was obtained on combined LLT and by 31.4° with the statin alone. Conclusion: significant progress in the development of cardiovascular imaging has made it possible to expand our understanding of the morphology of AP, the features of coronary vessel remodeling, and the development of acute cardiovascular complications.

show abstract

Section: The Role Of Imaging Methods In Evaluating the Effectiveness ...mentioning

confidence: 99%

“…Currently, the intensification of lipid-lowering therapy in patients with very high cardiovascular risk is considered as an effective and justified strategy. According to the latest version of the Russian guidelines on the management of lipid disorders (2023) [38]:…”

Section: The Role Of Imaging Methods In Evaluating the Effectiveness ...mentioning

confidence: 99%

Detection and Stabilization of Vulnerable Plaques in the Coronary Arteries

Bikbaeva¹,

Kovalskaya²,

Rodin³

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…• МГТ не рекомендована пациенткам с ИБС, а также с перенесенным острым нарушением мозгового кро- [60][61][62]. Следует отметить что, Лп(а) является независимым фактором риска ССЗ и, в частности, повторного ишемического инсульта [63,64]. Статинотерапия оказывает слабое влияние на уровень этого проатерогенного липопротеида, тогда как МГТ достоверно его снижает [65].…”

Section: ключевые положенияunclassified

Russian Eligibility Criteria for Prescribing Menopausal Hormone Therapy to Patients With Cardiovascular and Metabolic Diseases. Consensus Document of RSC, RSOG, RAE, EUAT, RAP

Shlyakhto,

Sukhikh,

Serov

et al. 2023

Kardiologiia

Self Cite

View full text Add to dashboard Cite

Menopausal symptoms can impair the life of women at the peak of their career and family life. At the present time, the most effective treatment for these manifestations is menopausal hormone therapy (MHT). The presence of cardiovascular and metabolic diseases in itself does not exclude the possibility of prescribing MHT to relieve menopausal symptoms and improve quality of life. However, often an obstacle to the use of this type of hormone therapy is the fear of physicians to do more harm to patients than good. Caution is especially important when it comes to women with concurrent diseases. Moreover, it should be recognized that there is a shortage of high-quality research on the safety of MHT for underlying chronic non-infectious diseases and common comorbidities. The presented consensus analyzed all currently available data from clinical trials of various designs and created a set of criteria for the appropriateness of prescribing MHT to women with concomitant cardiovascular and metabolic diseases. Based on the presented document, physicians of various specialties who advise menopausal women will receive an accessible algorithm that will allow them to avoid potentially dangerous situations and reasonably prescribe MHT in real-life practice.

show abstract

“…Снижение уровня ХС ЛНП на 1 ммоль / л уже сокращает риск развития ишемического инсульта на 12 % [14]. Согласно консенсусному мнению экспертов, целевым значением ХС ЛНП для пациентов очень высокого риска, в том числе и для пациентов, перенесших ИИ, следует считать менее 1,4 ммоль / л [15]. Несмотря на имеющие возможности по медикаментозной коррекции дислипидемии, достижение целевого значения в реальной клинической практике затруднено.…”

Section: Introductionunclassified

“…Обновленный подход подразумевает раннее использование комбинированной терапии у пациентов с ХС ЛНП выше 5,0 ммоль / л, в том числе с применением моноклональных антител и нового класса препаратов -малой интерферирующей РНК, единственным представителем которого является инклисиран. Данное положение отражено в новых клинических рекомендациях МЗ РФ «Нарушения липидного обмена» [15].…”

Section: Introductionunclassified

Inclisiran in patients with acute ischemic stroke: first data

Cherepianskii,

Ponomareva,

Skiba

et al. 2023

Kardiologiia

View full text Add to dashboard Cite

Aim. To evaluate the effect of inclisiran therapy on parameters of lipid metabolism in hospitalized patients with acute ischemic stroke.Material and methods. A prospective, observational, non-randomized study was performed. The study included 12 patients with acute ischemic stroke prescribed with a combination lipid-lowering therapy with inclisiran (284 mg as a single dose). At 15 days after the start of therapy, changes in blood lipid composition were assessed. For quantitative variables, median, maximum and minimum values were determined. The significance of differences between related samples in quantitative variables was assessed using the Mann-Whitney test.Results. Before the start of combination lipid-lowering therapy, total cholesterol (TC) was 7.33 mmol/l and low-density lipoprotein C (LDL-C) was 5.23 mmol/l. At 15 days after the start of inclisiran therapy, TC significantly decreased by 52.1 % and LDL-C decreased by 71.1 %. The proportion of patients who reached the LDL-C goal was 66.7 %. There were no adverse events considered by the investigators to be related with the therapy.Conclusion. The strategy of early administration of inclisiran (or its combination with a statin) in patients with ischemic stroke allows safe achievement of a significant reduction in LDL-C already in 15 days after the start of therapy.

show abstract

Disorders of lipid metabolism. Clinical Guidelines 2023

Cited by 73 publications

References 223 publications

Detection and Stabilization of Vulnerable Plaques in the Coronary Arteries

Detection and Stabilization of Vulnerable Plaques in the Coronary Arteries

Russian Eligibility Criteria for Prescribing Menopausal Hormone Therapy to Patients With Cardiovascular and Metabolic Diseases. Consensus Document of RSC, RSOG, RAE, EUAT, RAP

Inclisiran in patients with acute ischemic stroke: first data

Contact Info

Product

Resources

About